Impact BioMedical Inc.
IBO
$0.55
-$0.03-5.64%
AMEX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -61.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -61.11% | |||
| Cost of Revenue | -- | 42,100.00% | |||
| Gross Profit | 101.69% | -2,541.18% | |||
| SG&A Expenses | 590.18% | -46.71% | |||
| Depreciation & Amortization | -0.35% | -0.69% | |||
| Other Operating Expenses | -6.94% | -33.94% | |||
| Total Operating Expenses | 97.08% | 20.60% | |||
| Operating Income | -97.67% | -22.15% | |||
| Income Before Tax | -186.03% | 280.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -143.63% | 454.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -130.00% | 100.00% | |||
| Net Income | -143.60% | 456.80% | |||
| EBIT | -97.67% | -22.15% | |||
| EBITDA | -359.50% | -847.83% | |||
| EPS Basic | -136.30% | 148.42% | |||
| Normalized Basic EPS | -171.12% | 124.87% | |||
| EPS Diluted | -137.06% | 147.43% | |||
| Normalized Diluted EPS | -171.12% | 124.87% | |||
| Average Basic Shares Outstanding | 20.07% | 636.68% | |||
| Average Diluted Shares Outstanding | 20.07% | 636.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||